Age (years) 61.8 ± 8.9 BMI (units) 28.8 ± 5.5 Diabetes, n (%) 48 (34%) NYHA class III-IV, n (%) 46 (32.6%) LVEF, (%) 23.6 ± 5.7 6-minute walk test, (meters) 360 ± 69 Ischemic etiology, n (%) 76 (53.9%) QRS duration, (ms) 155 ± 23 IV delay ECHO, (ms) 42.7 ± 27.2 Intra LV delay (basal) – ECHO, (ms) 16.4 ± 69.2 β-blocker therapy, n (%) 137 (97.2%) ACE inhibitors / ARBs, n (%) 137 (97.2%) Digoxin, n (%) 63 (44.7%) Loop diuretic, n (%) 117 (83.0%) Spironolactone, n (%) 67 (47.5%)

Table 1: Characteristics of the study population. BMI: Body Mass Index; NYHA: New York Heart Association; n: Number; LVEF: left Ventricular Ejection Fraction; ms: minutes; IV: Interventricular; LV: left Ventricle; ACE: Angiotensin Converting Enzyme; ARBs: Angiotensin Receptor Antagonists.